BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 20085485)

  • 1. Vaccines against seasonal and pandemic influenza and the implications of changes in substrates for virus production.
    Minor PD
    Clin Infect Dis; 2010 Feb; 50(4):560-5. PubMed ID: 20085485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continuous cell lines as a production system for influenza vaccines.
    Genzel Y; Reichl U
    Expert Rev Vaccines; 2009 Dec; 8(12):1681-92. PubMed ID: 19943763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Selected problems of manufacturing influenza vaccines].
    Augustynowicz E
    Przegl Epidemiol; 2010; 64(3):373-80. PubMed ID: 20976949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell culture as a substrate for the production of influenza vaccines: memorandum from a WHO meeting.
    Bull World Health Organ; 1995; 73(4):431-5. PubMed ID: 7554013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccine production capacity for seasonal and pandemic (H1N1) 2009 influenza.
    Collin N; de Radiguès X;
    Vaccine; 2009 Aug; 27(38):5184-6. PubMed ID: 19563891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of 2008-09 trivalent influenza vaccine against 2009 pandemic influenza A (H1N1) - United States, May-June 2009.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2009 Nov; 58(44):1241-5. PubMed ID: 19910912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cell culture-derived influenza vaccines from Vero cells: a new horizon for vaccine production.
    Montomoli E; Khadang B; Piccirella S; Trombetta C; Mennitto E; Manini I; Stanzani V; Lapini G
    Expert Rev Vaccines; 2012 May; 11(5):587-94. PubMed ID: 22827244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Safety of cell culture-based influenza vaccines].
    Schmitt HJ; Gregersen JP; Trusheim H; Bröker M
    Med Monatsschr Pharm; 2010 Jan; 33(1):4-10. PubMed ID: 20131669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategies for developing vaccines against H5N1 influenza A viruses.
    Horimoto T; Kawaoka Y
    Trends Mol Med; 2006 Nov; 12(11):506-14. PubMed ID: 17011235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccines in development against avian influenza.
    Cox MM
    Minerva Med; 2007 Apr; 98(2):145-53. PubMed ID: 17519856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccines. Shifting tactics in the battle against influenza.
    Ault A
    Science; 2004 Feb; 303(5662):1280. PubMed ID: 14988531
    [No Abstract]   [Full Text] [Related]  

  • 12. Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans.
    Sandbulte MR; Jimenez GS; Boon AC; Smith LR; Treanor JJ; Webby RJ
    PLoS Med; 2007 Feb; 4(2):e59. PubMed ID: 17298168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Influenza vaccine: globalization of public health stakes].
    Collin N; Briand S
    Med Trop (Mars); 2009 Aug; 69(4):322. PubMed ID: 19725377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HPLC-based quantification of haemagglutinin in the production of egg- and MDCK cell-derived influenza virus seasonal and pandemic vaccines.
    Kapteyn JC; Porre AM; de Rond EJ; Hessels WB; Tijms MA; Kessen H; Slotboom AM; Oerlemans MA; Smit D; van der Linden J; Schoen P; Thus JL
    Vaccine; 2009 Feb; 27(9):1468-77. PubMed ID: 19110022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Harvesting and concentration of human influenza A virus produced in serum-free mammalian cell culture for the production of vaccines.
    Kalbfuss B; Genzel Y; Wolff M; Zimmermann A; Morenweiser R; Reichl U
    Biotechnol Bioeng; 2007 May; 97(1):73-85. PubMed ID: 16921531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Which response against the next influenza pandemic?].
    Snacken R
    Rev Med Brux; 1996 Dec; 17(6):400-2. PubMed ID: 9045272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Influenza A/H5N1 virus outbreaks and prepardness to avert flu pandemic].
    Haque A; Lucas B; Hober D
    Ann Biol Clin (Paris); 2007; 65(2):125-33. PubMed ID: 17353166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of an influenza A H5N2 reassortant as a candidate for live-attenuated and inactivated vaccines against highly pathogenic H5N1 viruses with pandemic potential.
    Desheva JA; Lu XH; Rekstin AR; Rudenko LG; Swayne DE; Cox NJ; Katz JM; Klimov AI
    Vaccine; 2006 Nov; 24(47-48):6859-66. PubMed ID: 17050041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of an attenuated H5N1 avian influenza virus vaccine with all eight genes from avian viruses.
    Shi H; Liu XF; Zhang X; Chen S; Sun L; Lu J
    Vaccine; 2007 Oct; 25(42):7379-84. PubMed ID: 17870216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microcarrier-based MDCK cell culture system for the production of influenza H5N1 vaccines.
    Hu AY; Weng TC; Tseng YF; Chen YS; Wu CH; Hsiao S; Chou AH; Chao HJ; Gu A; Wu SC; Chong P; Lee MS
    Vaccine; 2008 Oct; 26(45):5736-40. PubMed ID: 18761387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.